Adaptive Biotechnologies

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. 

CEO
Chad Robins
CEOChad Robins
Employees
619
Employees619
Headquarters
Seattle, Washington
HeadquartersSeattle, Washington
Founded
2009
Founded2009
Employees
619
Employees619

ADPT Key Statistics

Market cap
2.80B
Market cap2.80B
Price-Earnings ratio
-34.38
Price-Earnings ratio-34.38
Dividend yield
Dividend yield
Average volume
1.56M
Average volume1.56M
High today
$18.55
High today$18.55
Low today
$17.65
Low today$17.65
Open price
$18.41
Open price$18.41
Volume
1.54M
Volume1.54M
52 Week high
$20.76
52 Week high$20.76
52 Week low
$6.26
52 Week low$6.26

Stock Snapshot

As of today, Adaptive Biotechnologies(ADPT) shares are valued at $18.37. The company's market cap stands at 2.8B, with a P/E ratio of -34.38.

During the trading session on 2026-01-29, Adaptive Biotechnologies(ADPT) shares reached a daily high of $18.55 and a low of $17.65. At a current price of $18.37, the stock is +4.1% higher than the low and still -1.0% under the high.

Trading activity shows a volume of 1.54M, compared to an average daily volume of 1.56M.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $6.26.

Over the past 52 weeks, Adaptive Biotechnologies(ADPT) stock has traded between a high of $20.76 and a low of $6.26.

ADPT News

Simply Wall St 10h
Adaptive Biotechnologies Is Up 5.3% After Surging Revenue And Genentech Tie-Up Spotlighted - Has The Bull Case Changed?

Adaptive Biotechnologies, a commercial-stage biotech focused on the adaptive immune system, recently highlighted very large year-on-year revenue growth alongsid...

Adaptive Biotechnologies Is Up 5.3% After Surging Revenue And Genentech Tie-Up Spotlighted - Has The Bull Case Changed?
TipRanks 3d
Adaptive Biotechnologies price target raised to $21 from $20 at Guggenheim

Guggenheim raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $21 from $20 and keeps a Buy rating on the shares. The firm adjusted models, for...

Simply Wall St 5d
A Look At Adaptive Biotechnologies Valuation After Recent Share Price Rebound

Advertisement Context for the latest move in Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn investor attention after recent trading, with...

A Look At Adaptive Biotechnologies Valuation After Recent Share Price Rebound

Analyst ratings

88%

of 8 ratings
Buy
87.5%
Hold
12.5%
Sell
0%

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.